RAUWILOID Drug Patent Profile
When do Rauwiloid patents expire, and when can generic versions of Rauwiloid launch?
Rauwiloid is a drug marketed by 3M and is included in one NDA.
The generic ingredient in RAUWILOID is alseroxylon. There is one drug master file entry for this compound. Additional details are available on the alseroxylon profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RAUWILOID?
- What are the global sales for RAUWILOID?
- What is Average Wholesale Price for RAUWILOID?
Summary for RAUWILOID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 15 |
| Patent Applications: | 4,080 |
| DailyMed Link: | RAUWILOID at DailyMed |
US Patents and Regulatory Information for RAUWILOID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3m | RAUWILOID | alseroxylon | TABLET;ORAL | 008867-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
